Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Douglas Zipes MD
Douglas P. Zipes MD Editor-in-Chief
Paul Thompson MD
Paul D. Thompson MD Advisory Board
Anne Valente MD
Anne Marie Valente MD Advisory Board
See All Experts
featured
Published in Cardiology

Expert Opinion / My Approach · May 19, 2014

MY APPROACH to the Use of NOACs for Stroke Prevention in Patients With Atrial Fibrillation

Gregory Lip MD, FRCP, DFM, FACC, FESC

 

 Save  Recommend
 Share

Additional Info

  1. Husted S, De Caterina R, Andreotti F, et al. ESC Working Group on Thrombosis Task Force on Anticoagulants in Heart Disease. Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel. Thromb Haemost. 2014;111(5):781-782.
  2. Camm AJ, Lip GY, De Caterina R, et al. ESC Committee for Practice Guidelines-CPG; Document Reviewers. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation--developed with the special contribution of the European Heart Rhythm Association. Europace. 2012;14(10):1385-1413.
  3. De Caterina R, Husted S, Wallentin L, et al. Vitamin K antagonists in heart disease: Current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease. Thromb Haemost. 2013;110(6):1087-1107.
  4. Gallego P, Roldan V, Marín F, et al. Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation. Thromb Haemost. 2013;110(6):1189-1198.
  5. Apostolakis S, Sullivan RM, Olshansky B, Lip GY. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT2R2 score. Chest. 2013;144(5):1555-1563.
  6. Azoulay L, Dell'aniello S, Simon TA, et al. Initiation of warfarin in patients with atrial fibrillation: early effects on ischaemic strokes [published online ahead of print December 18, 2013]. Eur Heart J. doi: 10.1093/eurheartj/eht499.
  7. Huisman MV, Lip GY, Diener HC, et al. Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice. Thromb Haemost. 2012;107(5):838-847.
  8. Turpie AG, Kreutz R, Llau J, Norrving B, Haas S. Management consensus guidance for the use of rivaroxaban--an oral, direct factor Xa inhibitor. Thromb Haemost. 2012;108(5):876-886.

Further Reading

Most Read This Week

Recently Updated